Angel Kaifer

20120129199, May 24, 2012

May 19, 2010

13/321521

Pirouz M. Daftarian - Miami FL, US
Paolo Serafini - Miami Shores FL, US
Vance Paul Lemmon - Miami FL, US
Angel Kaifer - Coral Gables FL, US
Bonnie Beth Blomberg - Coral Gables FL, US
Raquibul Chowdhury - Miami FL, US
Norma Kenyon - Miami FL, US

UNIVERSITY OF MIAMI - Miami FL

G01N 33/566
C12N 5/078

435 792, 435375, 435 71

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein.

20120093761, Apr 19, 2012

Apr 1, 2010

13/262285

Pirouz M. Daftarian - Miami FL, US
Paolo Serafini - Miami Shores FL, US
Vance Paul Lemmon - Miami FL, US
Angel Kaifer - Coral Gables FL, US
Victor L. Perez - Pinecrest FL, US
Wei Li - Miami FL, US
Bonnie Beth Blomberg - Coral Gables FL, US

UNIVERSITY OF MIAMI - Miami FL

A61K 31/785
A61P 35/00
C12N 15/09
A61P 37/04
C08G 69/48
C12N 5/07

424 7817, 525 541, 435375, 435440

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

20200237928, Jul 30, 2020

Feb 17, 2020

16/792667

- Miami FL, US
Jennifer Vella - Lebanon NH, US
Vincenzo Bronte - Verona, IT
Pirouz Daftarian - Palmetto Bay FL, US
Angel Kaifer - Coral Gables FL, US
Serena Zilio - Miami FL, US

A61K 47/69
C12N 15/113
A61K 31/7105
A61K 47/60
C07K 7/06

Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a cell.

20190170742, Jun 6, 2019

Dec 20, 2018

16/228050

- Miami FL, US
Paolo SERAFINI - Miami Shores FL, US
Vance Paul LEMMON - Miami FL, US
Angel KAIFER - Coral Gables FL, US
Bonnie Beth BLOMBERG - Coral Gables FL, US
Raquibul CHOWDHURY - Miami FL, US
Norma KENYON - Miami FL, US

G01N 33/543
G01N 33/68
G01N 33/569
G01N 33/50
C12N 15/87

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immuno-logical responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein.

20180243443, Aug 30, 2018

Mar 3, 2016

15/553855

- Miami FL, US
Jennifer Vella - Lebanon NH, US
Vicenzo Bronte - Abano Terme, IT
Pirouz Daftarian - Palmetto Bay FL, US
Angel Kaifer - Coral Gables FL, US
Serena Zilio - Miami FL, US

A61K 47/69
C12N 15/113
A61K 47/59
A61K 49/00
A61K 47/64
A61K 31/683
A61K 31/713
A61P 35/00

Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a myeloid cell.

20180099032, Apr 12, 2018

Sep 15, 2017

15/705520

- Miami FL, US
Paolo Serafini - Miami FL, US
Vance Paul Lemmon - Miami FL, US
Wei Li - San Antonio TX, US
Angel Kaifer - Coral Gables FL, US
Bonnie Beth Blomberg - Coral Gables FL, US
Victor L. Perez - Miami FL, US

A61K 39/00
A61K 39/12
A61K 39/145
C08G 83/00

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

20170146526, May 25, 2017

Oct 5, 2016

15/286131

- MIAMI FL, US
Paolo SERAFINI - Miami Shores FL, US
Vance Paul LEMMON - Miami FL, US
Angel KAIFER - Coral Gables FL, US
Bonnie Beth BLOMBERG - Coral Gables FL, US
Raquibul CHOWDHURY - Miami FL, US
Norma KENYON - Miami FL, US

G01N 33/543
G01N 33/569
G01N 33/68

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein.